Title: Multicenter clinical trial of pioglitazone in the treatment of 2 type diabetes
Abstract: Objective To evaluate the efficacy and safety of pioglitazone in the treatment of type 2 diabetes. Methods Two hundreds and thirty six patients with type 2 diabetes who have received metformin and sulfonylureas treatment were included in this 12-week, multicenter, double-blind study. They were divided randomly into trial group (pioglitazone 30 mg one time a day) and contro group (placebo). Results Fasting and post prandial plasma glucose levels of the trial group decreased significantly (P 0.01 ). The mean levels of glycosylated hemoglobin levels decreased by 1.06 % (P0.01) in the trial group and by 0.51% (P0.01) in the control group. Meanwile, fasting and postprandial plasma insulin levels of the two groups unchanged significantly. High-density lipoprotein cholesterol increased by 0.11 mmol·L -1 (P0.01) and low-density lipoprotein cholesterol decreased by 0.21 mmol·L -1 (P0.01) in the trial group at week 12 vs baseline. Blood pressure of the trial group decreased significantly (P0.01). Body mass index increased (0.36, P0.01) in the trial group. One case in the trial group dropped off because of moderate liver damage, mild edema occurred frequently.The proportion of patients reporting other adverse experiences was comparable between two groups. Conclusion Treatment with pioglitazone 30 mg qd in patients plus previous metformin-sulfonylureas can improve glycemic control, improve insulin sensitivity and have possibility to improve lipid metabolism and hypertention. Pioglitazone 30 mg qd is generally all tolerated.
Publication Year: 2005
Publication Date: 2005-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot